Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [

64Cu-DOTA-AE105 Oral squamous cell carcinoma PET/CT Patient-derived xenograft models Urokinase-type plasminogen activator receptor

Journal

Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610

Informations de publication

Date de publication:
25 Sep 2023
Historique:
received: 06 06 2023
accepted: 08 09 2023
revised: 01 09 2023
medline: 26 9 2023
pubmed: 26 9 2023
entrez: 25 9 2023
Statut: aheadofprint

Résumé

[ PDX flank tumor models were established by engrafting tumor tissue from three patients with locally advanced OSCC into immunodeficient mice. [ Three PDX models were established, and all of them showed histological stability and unchanged heterogenicity, uPAR expression, and Ki67 expression through passages. A significant correlation between uPAR expression and tumor growth was found. All tumors of all models (n=29) showed tumor uptake of [ OSCC PDX models in early passages histologically mimic donor tumors and could serve as a valuable platform for the development of uPAR-targeted imaging and therapeutic modalities. Furthermore, [64Cu]Cu-uPAR-PET/CT showed target- and tumor-specific uptake in OSCC PDX models demonstrating the diagnostic potential of this modality for OSCC patients.

Identifiants

DOI: 10.1007/s11307-023-01858-x PMID: 37749438
pubmed: 37749438
doi: 10.1007/s11307-023-01858-x
pii: 10.1007/s11307-023-01858-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s).

Références

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/CAAC.21660
doi: 10.3322/CAAC.21660 pubmed: 33538338
Zanoni DK, Montero PH, Migliacci JC, Shah JP, Wong RJ, Ganly I, Patel SG (2019) Survival outcomes after treatment of cancer of the oral cavity (1985–2015). Oral Oncol 90:115–121. https://doi.org/10.1016/j.oraloncology.2019.02.001
doi: 10.1016/j.oraloncology.2019.02.001 pubmed: 30846169 pmcid: 6417804
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E et al (2014) Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 15:23–34. https://doi.org/10.1016/S1470-2045(13)70546-1
doi: 10.1016/S1470-2045(13)70546-1 pubmed: 24314615
Barrera JE, Miller ME, Said S, Jafek BW, Campana JP, Shroyer KR (2003) Detection of occult cervical micrometastases in patients with head and neck squamous cell cancer. Laryngoscope 113:892–896. https://doi.org/10.1097/00005537-200305000-00022
doi: 10.1097/00005537-200305000-00022 pubmed: 12792329
Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA, Bakholdt V, Krogdahl A, Von Buchwald C, Bilde A et al (2015) Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Eur J Cancer 51:2777–2784. https://doi.org/10.1016/j.ejca.2015.08.023
doi: 10.1016/j.ejca.2015.08.023 pubmed: 26597442
Amit M, Yen TC, Liao CT, Binenbaum Y, Chaturvedi P, Agarwal JP, Kowalski LP, Ebrahimi A, Clark JR, Cernea CR et al (2013) Clinical nodal stage is a significant predictor of outcome in patients with oral cavity squamous cell carcinoma and pathologically negative neck metastases: results of the international consortium for outcome research. Ann Surg Oncol 20:3575–3581. https://doi.org/10.1245/s10434-013-3044-0
doi: 10.1245/s10434-013-3044-0 pubmed: 23775408
Ding Z, Li Y, Pan X, Xuan M, Xie H, Wang X (2021) Sentinel lymph node biopsy versus elective neck dissection in squamous cell carcinoma of the oral cavity with a clinically n0 neck: systematic review and meta-analysis of prospective studies. Head Neck 43:3185–3198. https://doi.org/10.1002/HED.26803
doi: 10.1002/HED.26803 pubmed: 34245070
D’Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, Agarwal JP, Pantvaidya G, Chaukar D, Deshmukh A et al (2015) Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373:521–529. https://doi.org/10.1056/nejmoa1506007
doi: 10.1056/nejmoa1506007 pubmed: 26027881
Persson M, Juhl K, Rasmussen P, Brandt-Larsen M, Madsen J, Ploug M, Kjaer A (2014) UPAR targeted radionuclide therapy with 177Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer. Mol Pharm 11:2796–2806. https://doi.org/10.1021/mp500177c
doi: 10.1021/mp500177c pubmed: 24955765
Quigley NG, Steiger K, Hoberück S, Czech N, Zierke MA, Kossatz S, Pretze M, Richter F, Weichert W, Pox C et al (2022) PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the “cancer integrin” Αvβ6 with Ga-68-trivehexin. Eur J Nucl Med Mol Imaging 49:1136–1147. https://doi.org/10.1007/S00259-021-05559-X
doi: 10.1007/S00259-021-05559-X pubmed: 34559266
Durante S, Dunet V, Gorostidi F, Mitsakis P, Schaefer N, Delage J, Prior JO (2020) Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: a pilot study. EJNMMI Res 10. https://doi.org/10.1186/S13550-020-00638-W
van Loon J, Even AJG, Aerts HJWL, Öllers M, Hoebers F, van Elmpt W, Dubois L, Dingemans AMC, Lalisang RI, Kempers P et al (2017) PET imaging of zirconium-89 labelled cetuximab: a phase I Trial in patients with head and neck and lung cancer. Radiother Oncol 122:267–273. https://doi.org/10.1016/j.radonc.2016.11.020
doi: 10.1016/j.radonc.2016.11.020 pubmed: 28012793
Schöder H, de Souza França PD, Nakajima R, Burnazi E, Roberts S, Brand C, Grkovski M, Mauguen A, Dunphy MP, Ghossein RA et al (2020) Safety and feasibility of PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer. Clin Cancer Res 26:3110–3116. https://doi.org/10.1158/1078-0432.CCR-19-3484
doi: 10.1158/1078-0432.CCR-19-3484 pubmed: 32245901 pmcid: 7421489
Noh H, Hong S, Huang S (2013) Role of urokinase receptor in tumor progression and development. Theranostics 3:487–495
doi: 10.7150/thno.4218 pubmed: 23843896 pmcid: 3706692
Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH (2008) Evolving role of UPA/UPAR system in human cancers. Cancer Treat Rev 34:122–136. https://doi.org/10.1016/j.ctrv.2007.10.005
doi: 10.1016/j.ctrv.2007.10.005 pubmed: 18162327
Lawaetz M, Christensen A, Juhl K, Karnov K, Lelkaitis G, Fiehn A-MK, Kjaer A, von Buchwald C (2023) Potential of UPAR, Αvβ6 integrin, and tissue factor as targets for molecular imaging of oral squamous cell carcinoma: evaluation of nine targets in primary tumors and metastases by immunohistochemistry. Int J Mol Sci 24:3853. https://doi.org/10.3390/IJMS24043853
doi: 10.3390/IJMS24043853 pubmed: 36835265 pmcid: 9962929
Christensen A, Kiss K, Lelkaitis G, Juhl K, Persson M, Charabi BW, Mortensen J, Forman JL, Sørensen AL, Jensen DH et al (2017) Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer. BMC Cancer 17. https://doi.org/10.1186/s12885-017-3563-3
Boonstra MC, Verspaget HW, Ganesh S, FJGM K, Vahrmeijer AL, CJH v d V, PJK K, PHA Q, CFM S (2011) Clinical applications of the urokinase receptor (UPAR) for cancer patients. Curr Pharm Des 17:1890–1910. https://doi.org/10.2174/138161211796718233
doi: 10.2174/138161211796718233 pubmed: 21711239
Fosbøl MØ, Kurbegovic S, Johannesen HH, Røder MA, Hansen AE, Mortensen J, Loft A, Petersen PM, Madsen J, Brasso K et al (2021) Urokinase-type plasminogen activator receptor (UPAR) PET/MRI of prostate cancer for noninvasive evaluation of aggressiveness: comparison with gleason score in a prospective phase 2 clinical trial. J Nucl Med 62:354. https://doi.org/10.2967/JNUMED.120.248120
doi: 10.2967/JNUMED.120.248120 pubmed: 32764119 pmcid: 8049344
Carlsen EA, Loft M, Loft A, Berthelsen AK, Langer SW, Knigge U, Kjaer A (2022) Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: implications for uPAR targeted therapy. J Nucl Med 63(9):1371–1377. https://doi.org/10.2967/JNUMED.121.263177
doi: 10.2967/JNUMED.121.263177 pubmed: 35058319 pmcid: 9454472
Risør LM, Clausen MM, Ujmajuridze Z, Farhadi M, Andersen KF, Loft A, Friborg J, Kjaer A (2022) Prognostic value of urokinase-type plasminogen activator receptor PET/CT in head and neck squamous cell carcinomas and comparison with 18F-FDG-PET/CT: a single-center prospective study. J Nucl Med 63(8):1169–1176. https://doi.org/10.2967/jnumed.121.262866
doi: 10.2967/jnumed.121.262866 pubmed: 34857658 pmcid: 9364350
Ploug M, Østergaard S, Gårdsvoll H, Kovalski K, Holst-Hansen C, Holm A, Ossowski L, Danø K (2001) Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40:12157–12168. https://doi.org/10.1021/bi010662g
doi: 10.1021/bi010662g pubmed: 11580291
Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A (2017) Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med 58:451–457. https://doi.org/10.2967/jnumed.116.180430
doi: 10.2967/jnumed.116.180430 pubmed: 27660147
Persson M, Skovgaard D, Brandt-Larsen M, Christensen C, Madsen J, Nielsen CH, Thurison T, Klausen TL, Holm S, Loft A et al (2015) First-in-human UPAR PET: imaging of cancer aggressiveness. Theranostics 5:1303. https://doi.org/10.7150/THNO.12956
doi: 10.7150/THNO.12956 pubmed: 26516369 pmcid: 4615734
Christensen A, Juhl K, Persson M, Charabi BW, Mortensen J, Kiss K, Lelkaitis G, Rubek N, von Buchwald C, Kjær A (2017) UPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model. Oncotarget 8:15407–15419. https://doi.org/10.18632/oncotarget.14282
doi: 10.18632/oncotarget.14282 pubmed: 28039488
Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K (2022) Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med 20. https://doi.org/10.1186/S12967-022-03405-8
Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W et al (2017) Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol 28:2595. https://doi.org/10.1093/ANNONC/MDX416
doi: 10.1093/ANNONC/MDX416 pubmed: 28945830 pmcid: 5834154
Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goeŕé D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P et al (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18:5314–5328. https://doi.org/10.1158/1078-0432.CCR-12-0372/85035/AM/CHARACTERIZATION-OF-A-LARGE-PANEL-OF-PATIENT
doi: 10.1158/1078-0432.CCR-12-0372/85035/AM/CHARACTERIZATION-OF-A-LARGE-PANEL-OF-PATIENT pubmed: 22825584
Illemann M, Bird N, Majeed A, Lærum OD, Lund LR, Danø K, Nielsen BS (2009) Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 124:1860–1870. https://doi.org/10.1002/ijc.24166
doi: 10.1002/ijc.24166 pubmed: 19123477
Jacobsen B, Ploug M (2008) The urokinase receptor and its structural homologue c4.4a in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem 15:2559–2573. https://doi.org/10.2174/092986708785909012
doi: 10.2174/092986708785909012 pubmed: 18855679
Seshadri M, Merzianu M, Tang H, Rigual NR, Sullivan M, Loree TR, Popat SR, Repasky EA, Hylander BL (2009) Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts. Cancer Biol Ther 8(23):2275–83
doi: 10.4161/cbt.8.23.10137 pubmed: 19829072
Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, Armstrong EA, Blitzer GC, Smith MA, Lorenz LD et al (2013) Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res 19:855–864. https://doi.org/10.1158/1078-0432.CCR-12-2746
doi: 10.1158/1078-0432.CCR-12-2746 pubmed: 23251001
Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Woolfson A, Lorenzi MV, Bell D, Williams MD et al (2013) Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med 11. https://doi.org/10.1186/1479-5876-11-198
Cosper PF, Abel L, Lee YS, Paz C, Kaushik S, Nickel KP, Alexandridis R, Scott JG, Bruce JY, Kimple RJ (2020) Patient derived models to study head and neck cancer radiation response. Cancers (Basel) 12(2):419
doi: 10.3390/cancers12020419 pubmed: 32059418
Kang HN, Kim JH, Park AY, Choi JW, Lim SM, Kim J, Shin EJ, Hong MH, Pyo KH, Yun MR et al (2020) Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer. BMC Cancer 20. https://doi.org/10.1186/s12885-020-06786-5
Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7. https://doi.org/10.1038/S41598-017-17204-5
Goulding H, Pinder S, Cannon P, Pearson D, Nicholson R, Snead D, Bell J, Elston CWE, Robertson JF, Blamey RW et al (1995) A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 26:291–294. https://doi.org/10.1016/0046-8177(95)90060-8
doi: 10.1016/0046-8177(95)90060-8 pubmed: 7890280
Swick AD, Stein AP, McCulloch TM, Hartig GK, Ong IM, Sampene E, Prabakaran PJ, Liu CZ, Kimple RJ (2017) Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts. Oral Oncol 64:65. https://doi.org/10.1016/J.ORALONCOLOGY.2016.11.017
doi: 10.1016/J.ORALONCOLOGY.2016.11.017 pubmed: 28024726
Campbell KM, Lin T, Zolkind P, Barnell EK, Skidmore ZL, Winkler AE, Law JH, Mardis ER, Wartman LD, Adkins DR et al (2018) Oral cavity squamous cell carcinoma xenografts retain complex genotypes and intertumor molecular heterogeneity. Cell Rep. 24:2167–2178. https://doi.org/10.1016/j.celrep.2018.07.058
doi: 10.1016/j.celrep.2018.07.058 pubmed: 30134176 pmcid: 6417872
Makita H, Endo K, Kasahara Y, Nakata A, Moriyama-Kita M, Ishikawa K, Ueno T, Nakanishi Y, Kondo S, Wakisaka N et al (2021) Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties. Oncol Lett 21. https://doi.org/10.3892/OL.2021.12646
Rosfjord E, Lucas J, Li G, Gerber HP (2014) Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem Pharmacol 91:135–143
doi: 10.1016/j.bcp.2014.06.008 pubmed: 24950467
Li ZB, Niu G, Wang H, He L, Yang L, Ploug M, Chen X (2008) Imaging of urokinase-type plasminogen activator receptor expression using a 64cu-labeled linear peptide antagonist by MicroPET. Clin Cancer Res 14:4758–4766. https://doi.org/10.1158/1078-0432.CCR-07-4434
doi: 10.1158/1078-0432.CCR-07-4434 pubmed: 18676745
Persson M, Madsen J, Østergaard S, Jensen MM, Jørgensen JT, Juhl K, Lehmann C, Ploug M, Kjaer A (2012) Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med 53:138–145. https://doi.org/10.2967/jnumed.110.083386
doi: 10.2967/jnumed.110.083386 pubmed: 22213823
Persson M, Hosseini M, Madsen J, Jørgensen TJD, Jensen KJ, Kjaer A, Ploug M (2013) Improved PET imaging of UPAR expression using new 64Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies. Theranostics 3:618. https://doi.org/10.7150/THNO.6810
doi: 10.7150/THNO.6810 pubmed: 24052804 pmcid: 3776215
Persson M, El Ali HH, Binderup T, Pfeifer A, Madsen J, Rasmussen P, Kjaer A (2014) Dosimetry of 64Cu-DOTA-AE105, a PET tracer for UPAR imaging. Nucl Med Biol 41:290–295. https://doi.org/10.1016/j.nucmedbio.2013.12.007
doi: 10.1016/j.nucmedbio.2013.12.007 pubmed: 24533988
Persson M, Rasmussen P, Madsen J, Ploug M, Kjaer A (2012) New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177 Lu-DOTA-AE105 targeting UPAR in human colorectal cancer xenografts. Nucl Med Biol 39:962–969. https://doi.org/10.1016/j.nucmedbio.2012.05.007
doi: 10.1016/j.nucmedbio.2012.05.007 pubmed: 22739362
Zhai BT, Tian H, Sun J, Zou JB, Zhang XF, Cheng JX, Shi YJ et al (2022) Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. J Transl Med 20. https://doi.org/10.1186/s12967-022-03329-3

Auteurs

Mads Lawaetz (M)

Department of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. madslawaetz@gmail.com.
Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark. madslawaetz@gmail.com.

Tina Binderup (T)

Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

Anders Christensen (A)

Department of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

Karina Juhl (K)

Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

Giedrius Lelkaitis (G)

Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Eva Lykke (E)

Department of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Line Knudsen (L)

Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

Christian von Buchwald (C)

Department of Otolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Andreas Kjaer (A)

Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Copenhagen University Hospital - Rigshospitalet & Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

Classifications MeSH